Research article

Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome

JH Raphael¹ , JL Southall¹ , GJ Treharne² and GD Kitas³

¹  Department of Pain Management, Dudley Group of Hospitals NHS Trust, West Midlands, UK

²  School of Psychology, University of Birmingham, Edgbaston, Birmingham, UK

³  Department of Rheumatology, Dudley Group of Hospitals NHS Trust, West Midlands, UK

author email corresponding author email

BMC Musculoskeletal Disorders 2002, 3:21doi:10.1186/1471-2474-3-21

Published:	8 September 2002

Abstract

Background

To investigate the effects of intravenous lignocaine infusions (IV lignocaine) in fibromyalgia.

Methods

Prospective study of the adverse effects of IV lignocaine in 106 patients with fibromyalgia; retrospective questionnaire study of the efficacy of IV lignocaine in 50 patients with fibromyalgia.

Results

Prospective study: Two major (pulmonary oedema and supraventricular tachycardia) and 42 minor side-effects were reported. None had long-term sequelae. The commonest was hypotension (17 cases). Retrospective study: Pain and a range of psychosocial measures (on single 11-point scales) improved significantly after treatment. There was no effect of the treatment on work status. The average duration of pain relief after the 6-day course of treatment was 11.5 ± 6.5 weeks.

Conclusions

Intravenous lignocaine appears to be both safe and of benefit in improving pain and quality of life for patients with fibromyalgia. This needs to be confirmed in prospective randomised controlled trials.